December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

State Street SPDR S&P Biotech ETF (NY:XBI)

125.99 -1.68 (-1.32%)
Streaming Delayed Price Updated: 10:00 AM EST, Feb 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about State Street SPDR S&P Biotech ETF

< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
News headline image
Healthcare Stocks Hit New Highs but Small Caps Lag ↗
Many smaller cap biotech stocks trade on news and milestones and have no earnings so require more expertise in the field. 
Via Talk Markets
News headline image
ETF Reflections: US Stocks ↗
I'm a bear. So the longer they prop this dreck up, the greater the fall. Suits me! 
Via Talk Markets
News headline image
Biotech ETFs To Benefit From Latest Booster Update ↗
Vaccine makers like Moderna and Pfizer have reasons to cheer the update with regard to the application of boosters. The U.S. government announced plans to make COVID-19 vaccine boosters available from... 
Via Talk Markets
News headline image
Analyzing SPDR Series Trust SPDR S&P Biotech ETF's Unusual Options Activity ↗
On Monday, shares of SPDR Series Trust SPDR S&P Biotech ETF (NYSE:XBI) saw unusual options activity. After the option alert, the stock price moved down to $122.44. Sentiment... 
Via Benzinga
Topics Stocks
News headline image
Large Cap Biopharma Stocks provide Growth and Value ↗
The S&P 500 Healthcare Index was up 0.53% and biotech still lags in healthcare yet Large Cap Biopharma is doing well YTD. 
Via Talk Markets
Topics Stocks
Analyzing SPDR Series Trust SPDR S&P Biotech ETF's Unusual Options Activity ↗
SPDR Series Trust SPDR S&P Biotech ETF (NYSE:XBI) shares... 
Via Benzinga
Topics Stocks
Analyzing SPDR Series Trust SPDR S&P Biotech ETF's Unusual Options Activity ↗
SPDR Series Trust SPDR S&P Biotech ETF (NYSE:XBI) shares... 
Via Benzinga
Topics Stocks
Unusual Options Activity Insight: SPDR Series Trust SPDR S&P Biotech ETF ↗
On Friday, shares of SPDR Series Trust SPDR S&P Biotech ETF (NYSE: 
Via Benzinga
Topics Stocks
News headline image
ETF Investing Areas to Consider for August ↗
There is no doubt that the second-quarter 2021 earnings season is going strong. 
Via Talk Markets
News headline image
Carter Worth And Mike Khouw's XBI Trade ↗
On CNBC's "Options Action," Carter Worth of Cornerstone Macro said SPDR S&P Biotech ETF (NYSE: XBI) has a bounce potential, having sold off to support. XBI is an... 
Via Benzinga
Topics Stocks
Understanding SPDR Series Trust SPDR S&P Biotech ETF's Unusual Options Activity ↗
Shares of SPDR Series Trust SPDR S&P Biotech ETF (NYSE:XBI 
Via Benzinga
Topics Stocks
Unusual Options Activity Insight: SPDR Series Trust SPDR S&P Biotech ETF ↗
SPDR Series Trust SPDR S&P Biotech ETF (NYSE:XBI) shares... 
Via Benzinga
Topics Stocks
News headline image
Analyzing SPDR Series Trust SPDR S&P Biotech ETF's Unusual Options Activity ↗
Analyzing SPDR Series Trust SPDR S&P Biotech ETF's Unusual Options Activity Shares of SPDR Series Trust SPDR S&P Biotech ETF (NYSE: XBI) saw some unusual options activity... 
Via Benzinga
Topics Stocks
News headline image
Analyzing SPDR Series Trust SPDR S&P Biotech ETF's Unusual Options Activity ↗
On Thursday, shares of SPDR Series Trust SPDR S&P Biotech ETF (NYSE:XBI) saw unusual options activity. After the option alert, the stock price moved up to $126.24. Sentiment... 
Via Benzinga
Topics Stocks
News headline image
A Fresh Dose of Biotech Perspective ↗
If the only thing that’s changed with your favorite biotech is the price, stay the course. Your bottom line will thank you for it later. 
Via Talk Markets
News headline image
Understanding SPDR Series Trust SPDR S&P Biotech ETF's Unusual Options Activity ↗
Shares of SPDR Series Trust SPDR S&P Biotech ETF (NYSE:XBI) saw some unusual options activity on Monday. Following the unusual option alert, the stock price moved down to $132... 
Via Benzinga
Topics Stocks
News headline image
Mid-Cap Biotech Picks: Seasonal Rally Underway ↗
Many Mid-Cap biotech stocks were hit hard after the February peak. We suggest three new mid-cap biotech picks. All three picks can be volatile but very tradable. 
Via Talk Markets
News headline image
IBB Vs. XBI: Which Biotech ETF Has A Better Chart? ↗
The SPDR S&P Biotech ETF XBI is trading below an important resistance level, but the iShares Nasdaq Biotechnology ETF IBB has broken out. 
Via Talk Markets
Topics Stocks
News headline image
IBB Vs. XBI: Which Biotech ETF Has A Better Chart? ↗
The SPDR S&P Biotech ETF (NYSE: XBI) is trading below an important resistance level, but the iShares Nasdaq Biotechnology ETF (NASDAQ: IBB) has broken out. Resistance is a... 
Via Benzinga
Topics Stocks
News headline image
Why Regeneron Pharmaceuticals Analyst Says Competitive Concerns Are Overblown, Pipeline Opportunity Underappreciated ↗
Regeneron Pharmaceuticals Inc.'s (NASDAQ:REGN) robust ... 
Via Benzinga
News headline image
Healthcare Portfolio Playbook: Time To Rebalance With MedTech ↗
As we look to re-balance our portfolio in the near-term, investors should consider adding Medtech as we have suggested in the past. Though, more recently, we have also focused on large-cap... 
Via Talk Markets
News headline image
Should You Buy Biotech ETFs Now? ↗
Instead of trying to pick winners in this volatile space, it is better to invest in broader biotech ETFs that stand to benefit from increased investor interest and rising spending on drugs and... 
Via Talk Markets
News headline image
Tuesday Talk: Action! ↗
U.S. stock markets started the week in continued action mode. The S&P 500 closed at 4,255, up nearly 8 points, the Dow closed at 34,394, down 85 points and the Nasdaq Composite closed at 14,174, up... 
Via Talk Markets
Topics Stocks
News headline image
Biotechs Ready To Roar ↗
The biggest event last week was the FDA decision to approve Biogen's drug aducanumab, a treatment for Alzheimer's disease. The decision will reverberate across the industry and the healthcare sector... 
Via Talk Markets
News headline image
3 Biotech ETFs That Could Double Your Money by 2025 With Zero Effort ↗
In a sector where picking individual stocks is a high-risk, high-reward strategy, the diversification of exchange-traded funds can be highly appealing. 
Via The Motley Fool
News headline image
Analyzing SPDR Series Trust SPDR S&amp;P Biotech ETF's Unusual Options Activity ↗
SPDR Series Trust SPDR S&P Biotech ETF (NYSE:XBI) shares experienced unusual options activity on Friday. The stock price moved up to $136.19 following the option alert.... 
Via Benzinga
Topics Stocks
News headline image
Leisure & Entertainment ETF (PEJ) and AMC Networks (AMCX) Caught In Meme Madness ↗
Dynamic Leisure and Entertainment ETF (PEJ) has been by far the best performer over the past week. 
Via Talk Markets
News headline image
Stocks Drop On Turnaround Tuesday As The Next Leg Lower May Have Begun ↗
It was not a good day for the Russell 2000. After failing to break out yesterday, it fell sharply today. 
Via Talk Markets
News headline image
Biotech Stocks Cruise Through The Volatility ↗
The XLV Healthcare Select SPDR is up 10% YTD. 
Via Talk Markets
News headline image
Medical Miracles Inside Biotech ETFs ↗
The events of the past year focused a lot of attention on game changing developments made possible by the global biotech industry. Of the major names Moderna is the one where the original research and... 
Via Talk Markets
Topics Intellectual Property
< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.